The present invention is directed to the use of an effective amount of an isolated antibody that specifically binds an N-terminal portion of one or more PTHrP isoforms or a C-terminal portion of the PTHrP 1-173 isoform for inhibiting the growth and metastatis of cancer cells, more preferably wherein the antibody is a monoclonal antibody.